Search Results - "Shinozaki, Eiji"

Clinical utility of circulating tumor DNA for colorectal cancer by Osumi, Hiroki, Shinozaki, Eiji, Yamaguchi, Kensei, Zembutsu, Hitoshi

“…Colorectal cancer (CRC) is currently the most common type of cancer in Japan, and its prognosis has improved because of development of diagnosis and…”
Get full text

Immunotherapy in Colorectal Cancer: Current and Future Strategies by Ooki, Akira, Shinozaki, Eiji, Yamaguchi, Kensei

“…Despite the recent advances in the systemic treatment of metastatic colorectal cancer (mCRC), prognostic outcomes have remained to be poor. Thus, what is…”
Get full text

Enrichment of CLDN18‐ARHGAP fusion gene in gastric cancers in young adults by Nakayama, Izuma, Shinozaki, Eiji, Sakata, Seiji, Yamamoto, Noriko, Fujisaki, Junko, Muramatsu, Yusuke, Hirota, Toru, Takeuchi, Kengo, Takahashi, Shunji, Yamaguchi, Kensei, Noda, Tetsuo

“…Gastric cancer in young adults has been pointed out to comprise a subgroup associated with distinctive clinicopathological features, including an equal gender…”
Get full text

BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation by Nakayama, Izuma, Hirota, Toru, Shinozaki, Eiji

“…The Raf murine sarcoma viral oncogene homolog B (BRAF) mutation is detected in 8–12% of metastatic colorectal cancers (mCRCs) and is strongly correlated with…”
Get full text

A modified MethyLight assay predicts the clinical outcomes of anti‐epidermal growth factor receptor treatment in metastatic colorectal cancer by Ouchi, Kota, Takahashi, Shin, Okita, Akira, Sakamoto, Yasuhiro, Muto, Osamu, Amagai, Kenji, Okada, Takaho, Ohori, Hisatsugu, Shinozaki, Eiji, Ishioka, Chikashi

“…DNA methylation status correlates with clinical outcomes of anti‐epidermal growth factor receptor (EGFR) treatment. There is a strong need to develop a simple…”
Get full text

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer by Wakatsuki, Takeru, Yamamoto, Noriko, Sano, Takeshi, Chin, Keisho, Kawachi, Hiroshi, Takahari, Daisuke, Ogura, Mariko, Ichimura, Takashi, Nakayama, Izuma, Osumi, Hiroki, Matsushima, Tomohiro, Suenaga, Mitsukuni, Shinozaki, Eiji, Hiki, Naoki, Ishikawa, Yuichi, Yamaguchi, Kensei

“…Background There is growing interest in the clinical significance of intratumoral HER2 heterogeneity. Its prognostic and predictive impacts on trastuzumab…”
Get full text

Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database by Shinozaki, Eiji, Makiyama, Akitaka, Kagawa, Yoshinori, Satake, Hironaga, Tanizawa, Yoshinori, Cai, Zhihong, Piao, Yongzhe

“…The objectives were to describe treatment sequences for advanced colorectal cancer (CRC), use of second-line FOLFIRI (leucovorin, 5-fluorouracil, irinotecan)…”
Get full text

Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients by Fuse, Nozomu, Kuboki, Yasutoshi, Kuwata, Takeshi, Nishina, Tomohiro, Kadowaki, Shigenori, Shinozaki, Eiji, Machida, Nozomu, Yuki, Satoshi, Ooki, Akira, Kajiura, Shinya, Kimura, Tetsuo, Yamanaka, Takeharu, Shitara, Kohei, Nagatsuma, Akiko Kawano, Yoshino, Takayuki, Ochiai, Atsushi, Ohtsu, Atsushi

“…Background This study was conducted to investigate whether human epidermal growth factor receptor 2 (HER2) status, epidermal growth factor receptor (EGFR)…”
Get full text

Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival by Ota, Yumiko, Takahari, Daisuke, Suzuki, Takeshi, Osumi, Hiroki, Nakayama, Izuma, Oki, Akira, Wakatsuki, Takeru, Ichimura, Takashi, Ogura, Mariko, Shinozaki, Eiji, Suenaga, Mitsukuni, Chin, Keisho, Yamaguchi, Kensei

“…Purpose In the ATTRACTION-2 trial, nivolumab significantly improved the survival of advanced gastric cancer patients. The pretreatment neutrophil-to-lymphocyte…”
Get full text

Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research by Takahari, Daisuke, Shinozaki, Eiji, Wakatsuki, Takeru, Ooki, Akira, Ozaka, Masato, Suzuki, Takeshi, Nakayama, Izuma, Osumi, Hiroki, Kamiimabeppu, Daisaku, Sato, Taro, Ogura, Mariko, Suenaga, Mitsukuni, Chin, Keisho, Yamaguchi, Kensei

“…Coronavirus disease 2019 (COVID-19) was declared to be a global pandemic by the World Health Organization on March 11, 2020. On April 7, 2020, a state of…”
Get full text

REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer by Nakajima, Hiromichi, Kotani, Daisuke, Bando, Hideaki, Kato, Takeshi, Oki, Eiji, Shinozaki, Eiji, Sunakawa, Yu, Yamazaki, Kentaro, Yuki, Satoshi, Nakamura, Yoshiaki, Yamanaka, Takeharu, Yoshino, Takayuki, Ohta, Takashi, Taniguchi, Hiroya, Kagawa, Yoshinori

“…Previous clinical trials have demonstrated the potential efficacy of rechallenge with anti- epidermal growth factor receptor (EGFR) monoclonal antibodies…”
Get full text

Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer by Yagi, Shusuke, Wakatsuki, Takeru, Yamamoto, Noriko, Chin, Keisho, Takahari, Daisuke, Ogura, Mariko, Ichimura, Takashi, Nakayama, Izuma, Osumi, Hiroki, Shinozaki, Eiji, Suenaga, Mitsukuni, Fujisaki, Junko, Ishikawa, Yuichi, Yamaguchi, Kensei, Namikawa, Ken, Horiuchi, Yusuke

“…Background We recently reported the clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using surgical specimens; patients with…”
Get full text

Efficacy of aluminum chloride in severe regorafenib-associated hand-foot skin reactions: a single-arm trial by Nishizawa, Aya, Shinozaki, Eiji, Wakatsuki, Takeru, Satoh, Takahiro, Yamazaki, Naoya, Oyamada, Shunsuke, Ariyoshi, Keisuke, Kihara, Kota, Tsuboi, Masahiro, Yamaguchi, Kensei

“…Regorafenib, a multikinase inhibitor, causes a high frequency of hand-foot skin reactions (HFSRs). The present study evaluated the efficacy of topical aluminum…”
Get full text

Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy by Osumi, Hiroki, Shinozaki, Eiji, Nakamura, Yoshiaki, Esaki, Taito, Yasui, Hisateru, Taniguchi, Hiroya, Satake, Hironaga, Sunakawa, Yu, Komatsu, Yoshito, Kagawa, Yoshinori, Denda, Tadamichi, Shiozawa, Manabu, Satoh, Taroh, Nishina, Tomohiro, Goto, Masahiro, Takahashi, Naoki, Kato, Takeshi, Bando, Hideaki, Yamaguchi, Kensei, Yoshino, Takayuki

“…“Neo RAS WT” refers to the loss of RAS mutations (MTs) following first-line treatment in metastatic colorectal cancer (mCRC). We evaluate the incidence and…”
Get full text

A Multicenter Phase 2 Trial to Evaluate the Efficacy of mFOLFOX6 + Cetuximab as Induction Chemotherapy to Achieve R0 Surgical Resection for Advanced Colorectal Liver Metastases (NEXTO Trial) by Mise, Yoshihiro, Hasegawa, Kiyoshi, Saiura, Akio, Oba, Masaru, Yamamoto, Junji, Nomura, Yukihiro, Takayama, Tadatoshi, Hashiguchi, Yojiro, Shibasaki, Masayuki, Sakamoto, Hirohiko, Yamagata, Seiichi, Aoyanagi, Nobuyoshi, Kaneko, Hironori, Koyama, Hiroto, Miyagawa, Shinichi, Shinozaki, Eiji, Yoshida, Shuntaro, Nozawa, Hiroaki, Kokudo, Norihiro

“…Background The effect of cetuximab plus mFOLFOX on downsizing of the tumors for curative resection has yet to be assessed for patients with advanced colorectal…”
Get full text

Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer by Matsusaka, Satoshi, Chìn, Keisho, Ogura, Mariko, Suenaga, Mitsukuni, Shinozaki, Eiji, Mishima, Yuji, Terui, Yasuhito, Mizunuma, Nobuyuki, Hatake, Kiyohiko

“…The purpose of this study was to quantify circulating tumor cells (CTCs) in advanced gastric cancer (AGC) patients, and to demonstrate the role of CTCs in…”
Get full text

KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer by Shimozaki, Keitaro, Shinozaki, Eiji, Yamamoto, Noriko, Imamura, Yu, Osumi, Hiroki, Nakayama, Izuma, Wakatsuki, Takeru, Ooki, Akira, Takahari, Daisuke, Ogura, Mariko, Chin, Keisho, Watanabe, Masayuki, Yamaguchi, Kensei

“…Purpose Although RAS and PIK3CA mutations have been associated with resistance to anti-EGFR antibody in colorectal cancer or trastuzumab in breast cancer,…”
Get full text

Non‐V600E BRAF mutations and EGFR signaling pathway in colorectal cancer by Osumi, Hiroki, Shinozaki, Eiji, Wakatsuki, Takeru, Suenaga, Mitsukuni, Ichimura, Takashi, Ogura, Mariko, Takahari, Daisuke, Ooki, Akira, Suzuki, Takeshi, Ota, Yumiko, Nakayama, Izuma, Chin, Keisho, Miki, Yoshio, Yamaguchi, Kensei

“…The Raf murine sarcoma viral oncogene homolog B (BRAFV600E) mutation (MT) in metastatic colorectal cancer (CRC) is a well‐known prognostic indicator and a…”
Get full text

Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors by Fukuda, Koshiro, Osumi, Hiroki, Yoshino, Koichiro, Nakayama, Izuma, Fukuoka, Shota, Ogura, Mariko, Wakatsuki, Takeru, Ooki, Akira, Takahari, Daisuke, Chin, Keisho, Yamaguchi, Kensei, Shinozaki, Eiji

“…Few studies have focused on the impact of single-organ pulmonary metastases on progression-free survival and overall survival in patients with metastatic…”
Get full text

Druggable gene alterations in Japanese patients with rare malignancy by Ohmoto, Akihiro, Hayashi, Naomi, Fukada, Ippei, Yamazaki, Masumi, Yunokawa, Mayu, Kasuga, Akiyoshi, Shinozaki, Eiji, Ueki, Arisa, Tonooka, Akiko, Takeuchi, Kengo, Mori, Seiichi, Kiyotani, Kazuma, Takahashi, Shunji

“…Without a current standard of care, patients with rare malignancy are subjected to precision oncology with next-generation sequencing to identify a course of…”
Get full text